ArticleJournal for immunotherapy of cancer2020
Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy.
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Autophagy Modulates Immunogenic Cell Death in Cancer.Cancers · 2026Review
- A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.Journal of nanobiotechnology · 2025Article
- The inducible role of autophagy in cell death: emerging evidence and future perspectives.Cell communication and signaling : CCS · 2025Review
- Thiostrepton as a Potential Therapeutic Agent for Hepatocellular Carcinoma.International journal of molecular sciences · 2024Article
- Thiostrepton induces spindle abnormalities and enhances Taxol cytotoxicity in MDA-MB-231 cells.Molecular biology reports · 2024Article
- An antiviral oligomerized linear thiopeptide with a nitrile group from soil-derivedRSC advances · 2024Article
- Benzodiazepines compromise the outcome of cancer immunotherapy.Oncoimmunology · 2024Article
- Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.Oncoimmunology · 2024Review
- Repurposing thioridazine for inducing immunogenic cell death in colorectal cancer via eIF2α/ATF4/CHOP and secretory autophagy pathways.Cell communication and signaling : CCS · 2023Article
- Macrolide antibiotics activate the integrated stress response and promote tumor proliferation.Cell stress · 2023Article
- Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review.Frontiers in pharmacology · 2023Review
- Review
- Norcantharidin Induces Immunogenic Cell Death of Bladder Cancer Cells through Promoting Autophagy in Acidic Culture.International journal of molecular sciences · 2022Article
- Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.Oncoimmunology · 2022Article
- Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Journal for immunotherapy of cancer · 2022Article
- Autophagy activation by dietary piceatannol enhances the efficacy of immunogenic chemotherapy.Frontiers in immunology · 2022Article
- Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment.Frontiers in pharmacology · 2022Review
- Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.Cell death & disease · 2021Article
- Metabolic regulation in the immune response to cancer.Cancer communications (London, England) · 2021Review
- ATP and cancer immunosurveillance.The EMBO journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunogenic cell death (ICD) is a peculiar modality of cellular demise that elicits adaptive immune responses and triggers T cell-dependent immunity.
methodsFluorescent biosensors were employed for an unbiased drug screen approach aiming at the identification of ICD enhancers.
resultsHere, we discovered thiostrepton as an enhancer of ICD able to boost chemotherapy-induced ATP release, calreticulin exposure and high-mobility group box 1 exodus. Moreover, thiostrepton enhanced anticancer immune responses of oxaliplatin (OXA) in vivo in immunocompetent mice, yet failed to do so in immunodeficient animals. Consistently, thiostrepton combined with OXA altered the ratio of cytotoxic T lymphocytes to regulatory T cells, thus overcoming immunosuppression and reinstating anticancer immunosurveillance.
conclusionAltogether, these results indicate that thiostrepton can be advantageously combined with chemotherapy to enhance anticancer immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.